The Leeper laboratory studies the vascular biology of atherosclerosis and aneurysm disease.  We are interested in the molecular mechanisms that mediate vascular disease, and developing new translational therapies directed against them.  Our group uses a combination of hypothesis-free genetic approaches, favoring the concept that insights generated in this manner are likely to have relevance to human disease.  Currently, our major focus is on the chromosome 9p21 locus, which is widely recognized as the most important heritable cardiovascular locus identified through genome-wide association studies (GWAS).   We seek to fully explain how this locus - which affects over 20% of the population - potentiates coronary disease, stroke and aneurysms, and does so independently of all classical risk factors.   Our group pursues the goal of true ‘bench-to-bedside’ translation, and includes a basic genetics, molecular biology and mouse model team, as well as a translational Vascular Medicine team which performs early-phase clinical research.  Ultimately, we seek to develop a platform of new therapies directed against atherosclerosis, which is now the leading killer worldwide. 


News, Events, & Team Milestones

Publication in Nature

Experimental anticancer drug may tackle heart disease, too.  

First International Plaqomics Leducq Consortium Conference

Dr. Leeper attended the first International Plaqomics Leducq Consortium conference hosted by Visiting Professor Jeanette Erdmann in Lubeck, Germany.

Conference Video Highlights

Dr. Leeper awarded the American Heart association Established Investigator Award

Congratulations to Dr. Nicholas Leeper, Assistant Professor of Surgery and Medicine for receiving the Established Investigator Award (EIA) from the American Heart Association (AHA).  Per the AHA, this award is designed “to support mid-career investigators with unusual promise and established records of accomplishments”.   The Leeper lab plans to use this support to investigate emerging immunological aspects of atherosclerosis, with a focus on developing new translational therapies designed to suppress vascular inflammation.

Dr. Leeper Named as Trustee of the Society for Vascular Medicine

Dr. Leeper has been nominated to serve a second term as a Trustee of the Society for Vascular Medicine.  The Society for Vascular Medicine is a professional organization that was founded in 1989 for a broad mission of improving the integration of vascular biology advances into medical practice.  We are honored that Dr. Leeper serves as Trustee.